令和 4 年度 第 21 回 大学院セミナー

令和 4 年 7 月 19 日

分 野 名	医歯薬学総合研究科 放射線医療科学専攻 血液内科学分野(原研内科) 責任者名(宮﨑泰司) 内線(7111)
(責任者名)(内線)	
演 題	第 162 回原研研究集会
	GENKEN research seminar
講師等	原研内科(血液内科) 安東恒史 講師
HIS HIP VI	Koji Ando lecturer
概要	Adult T-cell leukemia/lymphoma (ATL) is an intractable disease with a poor prognosis. Recent studies have revealed that super-enhancers (SEs) play an important role in regulating tumor-specific gene expression and are expected to be therapeutic targets for neoplastic diseases, including ATL. Bromodomain-containing protein 4 (BRD4) is a complex of transcription factors that bind to the SE region. JQ1 is one of the BRD4 inhibitors, which exerts its antitumor effects by suppressing SE-mediated gene expression regulation. JQ1 has potential as a therapeutic agent in various malignancies, but has not yet been clinically applied. In this study, we investigated the anti ATL effect of JQ1 and identified RUNX1 as a novel therapeutic target molecule by elucidating its mechanism of anti ATL effect. Previous studies have suggested the efficacy of RUNX1 inhibitors such as AI-10-104 and Ro5-3335 in hematological malignancies such as AML and T-ALL. In this study, both drugs showed inhibition of cell proliferation at concentrations that were effective against AML and T-ALL. Thus, RUNX1 is a therapeutic target molecule, and RUNX1 inhibitors may represent a novel therapeutic approach for ATL. We demonstrated that JQ1 suppressed SE-mediated RUNX1 expression. We also suggested the efficacy of RUNX1 inhibitors against ATL and the mechanism of anti-ATL effect with RUNX1 inhibitors, which may lead to future clinical applications of RUNX1 inhibitors.
開催日時	令和4年 7月 27 日(水) 17:30 ~ 19:00
開催方法	Zoom
備考	受講を希望する場合は、ID・パスワードをお教えしますので、必ずご連絡ください。(内線 7111 or Email:k-seven@nagasaki-u.ac.jp) If you would like to participate in this seminar and need Zoom ID and Password, please contact below email address. (Email: k-seven@nagasaki-u.ac.jp Ext. 7111)

口先端医療科学特論(基礎編)	□先端医療科学特論(臨床編)
□先端新興感染症病態制御学特論	■先端放射線医療科学特論
□日本語(Japanese)	■英語(English)
口対面(Face to face)	■オンライン(Online)